Deutsche Bank upgrades Roche Holding stock to Buy at CHF 500.00

Published on 10/27/2026 at 17:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales rose 6.00 percent in nine months. Roche Holding stock costs EUR 431.33 on October 27, 2026, 0.80 percent below the Xetra close.

Analyst target and sales growth

Deutsche Bank upgraded Roche Holding to Buy and set a CHF 500.00 target on October 23, 2026.
Roche reported first-nine-month sales of CHF 46.493 billion, up 6.00 percent at constant exchange rates.
Roche Holding stock costs EUR 431.33 at Lang & Schwarz on October 27, 2026 at 5:52 p.m. CEST, 0.80 percent below the Xetra close of October 26, 2026.

Roche Holding, CH1499059983, Illustration mit AI erstellt.

Deutsche Bank upgraded Roche Holding to Buy and set a CHF 500.00 price target on October 23, 2026, as reported by Markets Insider. The target gives the analyst view a concrete level, while the stock was trading at EUR 431.33 at Lang & Schwarz on October 27, 2026 at 5:52 p.m. CEST, down 0.80 percent versus the Xetra close of October 26, 2026 at EUR 434.80.

Sales growth has two speeds

Roche reported group sales of CHF 46.493 billion for the first nine months of 2026, compared with CHF 45.862 billion in the same period of 2025. According to Roche on October 22, sales increased 6.00 percent at constant exchange rates but only 1.00 percent when reported in Swiss francs. The difference puts currency effects alongside operating growth.

The Pharmaceuticals Division generated CHF 36.212 billion in the period, up 7.00 percent at constant exchange rates and 2.00 percent in Swiss francs. Diagnostics contributed CHF 10.281 billion, up 4.00 percent at constant exchange rates and unchanged in Swiss francs. The figures show that pharmaceuticals supplied the larger share of reported growth.

Stock sits near its yearly high

Roche Holding stock stood 0.81 percent below its EUR 434.85 52-week high dated October 25, 2026, with the 52-week low at EUR 278.50. The stock was also up 23.14 percent year to date through October 26, 2026. These levels place the current euro quotation near the top of its annual range even after the 0.80 percent daily decline.

Analyst levels and dates

RBC maintained a Buy rating and a CHF 400.00 target on October 22, 2026, according to MarketScreener. The same report listed a CHF 390.90 last close and 21 analysts in its consensus table. Roche's next investor event listed on its calendar is the Berenberg Pharma CFO Series on November 2, 2026, followed by the Annual General Meeting on March 9, 2027, according to Roche.

Target levels frame the stock

The CHF 500.00 Deutsche Bank target and CHF 400.00 RBC target point to different assumptions about Roche's growth path. The latest operating data provide a measurable counterweight: nine-month pharmaceutical sales grew 7.00 percent at constant exchange rates, while diagnostics sales grew 4.00 percent.

Roche Holding stock after hours

The stock was trading at EUR 431.33 at Lang & Schwarz on October 27, 2026 at 5:52 p.m. CEST, 0.80 percent below the Xetra close of October 26, 2026 at EUR 434.80. The quotation remains 0.81 percent below the EUR 434.85 52-week high dated October 25, 2026. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.